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Deletion of UBE3A causes the neurodevelopmental
disorder Angelman syndrome (AS), while duplication
or triplication ofUBE3A is linked to autism. These ge-
netic findingssuggest that theubiquitin ligase activity
of UBE3A must be tightly maintained to promote
normal brain development. Here, we found that pro-
tein kinaseA (PKA) phosphorylatesUBE3A in a region
outside of the catalytic domain at residue T485 and
inhibits UBE3A activity toward itself and other sub-
strates. A de novo autism-linked missense mutation
disrupts this phosphorylation site, causing enhanced
UBE3A activity in vitro, enhanced substrate turnover
in patient-derived cells, and excessive dendritic
spine development in the brain. Our study identifies
PKA as an upstream regulator of UBE3A activity
and shows that an autism-linked mutation disrupts
this phosphorylation control. Moreover, our findings
implicate excessive UBE3A activity and the resulting
synaptic dysfunction to autism pathogenesis.INTRODUCTION
Autism is a genetically heterogeneous disorder associated with
synaptic deficits, social impairment, and stereotyped behaviors.
Recent studies indicate that copy-number variations and de
novo mutations in hundreds of genes can increase the risk for
autism (Chen et al., 2015; De Rubeis et al., 2014; Iossifov
et al., 2014). While some of these recently identified de novo
mutations introduce stop codons and hence likely disrupt gene
function, most introduce missense mutations of unknown signif-
icance (Iossifov et al., 2014). How these missense mutations—
representing the bulk of what has been discovered in exome
sequencing studies—affect protein function or contribute to dis-
ease is currently unknown.
Intriguingly, we noticed that one of these missense mutations
was in UBE3A. UBE3A is associated with cervical cancer and
two neurodevelopmental disorders—Angelman syndrome (AS)
and autism. Duplication or triplication of maternally inherited
15q11-13, the chromosomal location where UBE3A resides, isone of the most common cytogenetic events associated with
autism (Glessner et al., 2009; Hogart et al., 2010). Individuals
with one extra maternal copy of 15q11-13 display partial autism
penetrance, whereas individuals with two extra copies display
almost complete penetrance (Hogart et al., 2010; Urraca et al.,
2013). UBE3A is the only gene in this region that is consistently
expressed from the maternal, but not paternal, allele in mature
neurons (Albrecht et al., 1997; Rougeulle et al., 1997; Vu and
Hoffman, 1997), suggesting that abnormally elevated levels of
UBE3A contribute to autism in 15q11-13 duplication syndrome.
However, UBE3A is not the only gene duplicated in this syn-
drome, and pathogenicity in individuals with paternal 15q11-13
duplication has been reported, raising the possibility that addi-
tional genes in the region might increase autism risk (Germain
et al., 2014; Urraca et al., 2013).
There is no doubt that deletion or null mutation of the maternal
UBE3A allele causes AS, a disorder characterized by a happy
demeanor with frequent smiling, speech impairment, severe
intellectual disability, motor dysfunction, and seizures (Jiang
et al., 1998; Kishino et al., 1997; Mabb et al., 2011). In mice, dele-
tion of Ube3a impairs synapse development and plasticity and
recapitulates several neurobehavioral symptoms of AS (Greer
et al., 2010; Jiang et al., 1998; Margolis et al., 2010; Sato and
Stryker, 2010; Wallace et al., 2012; Yashiro et al., 2009).
UBE3A encodes a HECT domain E3 ubiquitin ligase that tar-
gets substrate proteins, including itself, for degradation (de Bie
and Ciechanover, 2011). Given that loss of UBE3A causes AS
while increases in UBE3A are associated with autism, UBE3A
levels andactivity are likely tobeunder tight control during normal
brain development. Autoregulation of UBE3A via self-targeted
degradation is cited as a mechanism for maintaining UBE3A
levels (de Bie and Ciechanover, 2011; Mabb et al., 2011; Nuber
et al., 1998). However, such a mechanism is likely to be overly
simplistic, asuncheckedself-degradationcould lead to self-elim-
ination. We thus speculated that additional mechanisms might
exist to control UBE3A activity. Here, we systematically exam-
ined how a large number of disease-linkedUBE3Amissensemu-
tations affect protein levels and activity. These analyses revealed
that UBE3A is inhibited by PKA phosphorylation at T485, a site
that was recently found to bemutated in an autism proband (Ios-
sifov et al., 2014). Mutation of this phosphorylation site abnor-
mally elevates UBE3A activity and increases synapse number
in vivo. Our study describes an upstream regulatory mechanismCell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc. 795
Figure 1. Characterization of UBE3A Missense Mutations
(A) Schematic showing humanUBE3Awith known functional domains, N-terminal zinc finger domain (Lemak et al., 2011), the location of non-truncating AS-linked
mutations (black), and the de novo missense mutation identified in an autism proband (red). Mutations tested in our study are shown in bold and include benign
variants (boxed).
(B) Approach used to determine how missense mutations disrupt UBE3A function. Mutations were introduced into a ligase-dead (LD, C820A) version of UBE3A.
These mutants were expressed in HEK293T cells to identify mutations that were (1) unstable independent of UBE3A activity (all relative to UBE3A-LD). For the
remaining stable mutants, ligase activity was restored (+Ligase) and the resulting constructs were transfected into HEK293T cells. This allowed us to identify
mutations that (2) resulted in hyperactivity (these mutants would be detected at lower levels relative to WT UBE3A) or (3) reduced catalytic activity (these mutants
would be detected at higher levels relative to WT UBE3A). Lastly, any UBE3A mutation (in +Ligase background) that was detected at equal levels relative to WT
UBE3A was tested for its ability to target HHR23A for ubiquitination. This allowed us to identify mutations that (4) affect substrate targeting without affecting self-
targeted degradation or that are benign polymorphisms.for UBE3A and provides a comprehensive understanding of how
missense mutations linked to AS and autism affect UBE3A pro-
tein function.
RESULTS
AS-Linked Missense Mutations Inactivate UBE3A via
Distinct Mechanisms
Most cases of AS arise due to a deletion of the maternal copy of
UBE3A, but some AS patients (10%) harbor missense muta-
tions in the coding region of UBE3A (Sadikovic et al., 2014).
Some of these AS-linked mutations cluster near the catalytic
cysteine (C820) and disrupt the ubiquitin ligase activity of
UBE3A (Sadikovic et al., 2014). However, the majority of these
mutations are located far from the catalytic site. Precisely how
most of these mutations, each of which changes a single amino
acid, disrupt UBE3A function has not been resolved. After map-
ping all reported AS-linked missense mutations relative to the
known domains in UBE3A, we noticed that these missense mu-
tations were not randomly distributed but, rather, were clustered
within distinct regions (Figure 1A). Based on this observation, we
hypothesized that there might be additional domains within
UBE3A that control enzyme activity or stability.
Like most E3 ubiquitin ligases, UBE3A mediates the ubiquiti-
nation of target proteins and itself (de Bie and Ciechanover,
2011; Kumar et al., 1999). These missense mutations could
thus disrupt UBE3A in four different ways, each of which can
be distinguished experimentally (Figure 1B and Table S1): (1)
by affecting protein stability independent of ligase activity, (2)796 Cell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc.by promoting self-targeted degradation, (3) by disrupting the
catalytic domain, or (4) by preventing UBE3A from targeting
substrates for degradation. To determine whether AS-linked
missensemutations affect UBE3A stability independent of ligase
activity, we introduced missense mutations (Figure 1A, high-
lighted in bold) into a ligase-dead (LD; C820A) version of human
UBE3A, transfected expression constructs into HEK293T cells,
and then monitored protein levels by western blotting. Of the
18 mutations tested, the protein levels of 8 were significantly
lower than UBE3A-LD control (Figures 2A and 2B and Table
S1). These data indicate that many AS-linked missense muta-
tions destabilize UBE3A independent of its ligase activity.
We then introduced the remaining seven mutations into cata-
lytically active wild-type (WT) UBE3A and found that protein
levels of two mutants (T106P and I130T) were significantly lower
than WT UBE3A, whereas the R482P mutant was detected at
significantly higher levels (Figures 2C and 2D and Table S1).
These findings suggested that the T106P and I130T mutations
promoted hyperactive self-degradation of UBE3A, a novel
gain-of-function mechanism that reduces UBE3A levels, while
the R482P mutation impaired UBE3A activity. Endogenous
UBE3A activity did not contribute to the effects of thesemutants,
as endogenous enzyme levels were very low in HEK293T cells
(Figure S1A). We tested additional AS-linked missense muta-
tions at T106 or near R482. T106K promoted self-degradation
like T106P, while R477P and M478I impaired activity like
R482P (Figures S1B–S1E and Table S1).
In further support that the T106P and I130Tmutations promote
self-degradation, protein levels of these mutants were rescued
Figure 2. AS-Linked Missense Mutations in UBE3A Cause Loss-of-Function via Distinct Mechanisms
(A andB)Representativewesternblot of protein levels for AS-linkedmutations introduced into ligase-dead (LD)UBE3Aandquantification (B). All UBE3Aconstructs
wereMyc tagged, contained an IRES-GFP to normalize for expression and transfection efficiency, and were transfected into HEK293T cells. Values are shown as
the percent ± SE of UBE3A-LD levels. n = 3–6/condition; *p < 0.05, **p < 0.005, ***p < 0.0005. See Supplemental Information for detailed statistical methods.
(C and D) Representative western blot of UBE3A mutants that possess ubiquitin ligase activity (+Ligase) and quantification (C). Values are shown as the mean
percent ± SE of WT UBE3A levels. n = 4, *p < 0.05, **p < 0.005, ***p < 0.0005.
(E–G) Immunofluorescence staining of Myc-tagged UBE3A and mutants in DIV 10 mouse cortical neurons. Scale bar, 15 mm. Raw intensity values for Myc
immunofluorescence (F) or Myc immunofluorescence normalized to GFP (G) are shown as the mean ± SE. n = 16–19 neurons/condition. *p < 0.05, ***p < 0.0005.(elevated) following proteasomal inhibition with MG-132 (Fig-
ure S1F and S1G), and high molecular weight polyubiquitinated
conjugates were detected on thesemutants only when the ligase
domain was intact (Figure S1H). Conversely, polyubiquitinated
UBE3A conjugates were not detected on the R482P mutant
(Figure S1H) and were absent or reduced for the R477P and
M478I mutants (Figure S1I), suggesting that these mutants had
little or no ubiquitin ligase activity. Likewise, when transfected
into primary mouse cortical neuron cultures, the protein levels
of the T106P and I130P mutants were lower relative to WT
UBE3A, while the R482P mutant was detected at higher levels
(Figures 2E–2G).We next evaluated the extent to which the T106P, I130T,
and R482P mutants targeted the UBE3A substrate HHR23A
for degradation in HEK293T cells (Kumar et al., 1999). We
found that protein levels of the UBE3A T106P and I130T mu-
tants were low relative to WT UBE3A, and HHR23A levels
were unaffected (Figures S1J and S1K). Moreover, the
T106P and I130T mutants did not effectively polyubiquitinate
HHR23A in cells that were treated with the proteasome
inhibitor MG-132 (Figure S1L). These data collectively suggest
that the T106P and I130T mutations endowed a gain of
function that was specific for UBE3A self-degradation, which
paradoxically drives UBE3A loss of function. In contrast, theCell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc. 797
Figure 3. UBE3A Is Phosphorylated at T485
In Vivo
(A) Sequence alignment showing conservation of
human UBE3A residues 473–538. Green boxes
indicate non-conserved residues, asterisks indi-
cate phosphorylation identified by mass spec-
trometry, T485 is highlighted in red, and arrow-
heads indicate potential phosphorylation sites.
(B) A phosphatase-sensitive UBE3A band is
recognized by the UBE3A (pT485) antibody in
brain lysates. Numbers indicate the mean ratio of
UBE3A pT485 intensity to total UBE3A intensity ±
SE. n = 3, *p < 0.05.
(C) Protein lysates from DIV 10 WT and Ube3a-
deficient (Ube3am/p+) cortical neuron cultures
were probed with the UBE3A pT485 antibody. The
small amount of UBE3A remaining originates from
non-neuronal cells that biallelically express
UBE3A. Phospho-UBE3A levels were normalized
to the neuron-specific marker Tuj1 and are shown
as the mean intensity ± SE. n = 3, *p < 0.05.
(D) Confocal projections of UBE3A pT485 and total
UBE3A in dissociated DIV 10 cortical neurons from
WT and Ube3am–/p+ embryos. Cells were trans-
fected with GFP and labeled by immunofluores-
cence for UBE3A pT485 and total UBE3A. Arrows
mark cells transfected with GFP. Scale bar, 15 mm.
The mean intensity ± SE for pT485 immunofluo-
rescence is indicated. WT, n = 20; Ube3am/p+
n = 20, ***p < 0.0005.UBE3A R482P mutation elevated protein levels of UBE3A and
HHR23A (Figures S1J and S1K), further indicating loss of
function.
The remaining four mutations (R39H, A178T, I329T, E550L) did
not significantly alter UBE3A protein levels (Figures 2C and 2D
and Table S1). Two of these mutations (R39H and A178T) are
now recognized as benign variants and are not associated with
AS (Malzac et al., 1998; Sadikovic et al., 2014). The E550L
mutant does not effectively target the UBE3A substrate
HHR23A for ubiquitination (Cooper et al., 2004), but how
the I329T mutation affects UBE3A function is unknown (Cam-
prubı´ et al., 2009). To determine whether the I329T mutant is
also defective in targeting substrates, we examined poly-
ubiquitination of HHR23A relative to three controls (R39H,
A178T, and E550L). As expected, we found that the benign
R39H and A178T variants polyubiquitinated HHR23A at levels
similar to WT UBE3A (Figure S1M). In contrast, the I329T mutant
behaved like the E550L mutant and did not polyubiquitinate
HHR23A to the same extent as WT UBE3A (Figure S1M). This
reduction in substrate ubiquitination was reflected in steady-
state HHR23A levels, which were elevated when co-expressed
with the I329T and E550L mutants (Figures S1N and S1O).
Collectively, our data indicate that AS-linked missense798 Cell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc.mutations inactivate UBE3A via distinct
mechanisms: (1) through ligase-indepen-
dent protein destabilization, (2) through
enhanced ligase-dependent degradation
of itself only, or (3) through failure to target
substrates for ubiquitination. These ex-periments reveal how numerous AS-linked mutations disrupt
UBE3A function and hence contribute to AS.
Phosphorylation Inhibits UBE3A
The R477P, M478I, and R482P mutations are tightly clustered
with other missense mutations (Figure 1A) and are located within
the a1 helix of UBE3A, a highly conserved structural element that
controls enzyme activity in other HECT domain ubiquitin ligases
(Pandya et al., 2010; Ronchi et al., 2014). In addition, arginine 482
forms a canonical PKA consensus motif (Songyang et al., 1994),
with threonine 485 (T485) as the putative phospho-acceptor res-
idue (Figure 3A). Given that other disease-relevant ubiquitin li-
gases are regulated by phosphorylation (Cohen, 2014; Ko
et al., 2010), these observations suggested that phosphorylation
at this site might control UBE3A activity. In support of this possi-
bility, we found that T485 was phosphorylated using mass spec-
trometry (Figure S2A). We then generated a phospho-T485
(pT485) antibody and confirmed its specificity experimentally.
(1) This antibody did not recognize UBE3A when T485 was
mutated to alanine (T485A), a residue that cannot be phosphor-
ylated (Figures S2B and S2C). (2) The antibody recognized a
single band at110 kD in whole-brain lysates that was sensitive
to phosphatase treatment (Figure 3B). (3) This antibody was
specific for UBE3A, as staining was detected in cultured cortical
neurons fromWTmice by western blot (Figure 3C) and by immu-
nocytochemistry (Figure 3D) but was not detected in cultures
from UBE3A-deficient (Ube3am–/p+) mice, which model AS. In
immature neurons cultured for 10 days in vitro (DIV 10), phos-
pho-UBE3A staining was cytoplasmic and present in dendritic
and axonal projections but was largely excluded from the nu-
cleus (Figures 3D, S2E, and S2F). This contrasted with total
UBE3A, which was also in the nucleus (Figures 3D, S2E, and
S2F). In mature neurons (DIV 18), UBE3A staining was predom-
inantly nuclear, as expected (Sato and Stryker, 2010; Yashiro
et al., 2009), while weak phospho-UBE3A immunoreactivity
was detected in the cytoplasm and in dendritic spines (Figures
S2G and S2H). These data suggest that endogenous UBE3A is
phosphorylated at T485 in neurons and is excluded from the
nucleus relative to total UBE3A.
To study the functional significance of T485 phosphorylation,
we transfected HEK293T cells with UBE3A constructs harboring
the T485A mutation (which cannot be phosphorylated; Figures
S2B and S2C) or a phospho-mimetic (T485E) mutation. We found
that the T485Amutantwasdetected at low levels (40.0%± 4.9%),
whereasa ligase-deadversionofT485A (T485A,LD)wasdetected
at higher levels (204.7% ± 26.5%) relative to WT UBE3A (Figures
4A and 4B). The phospho-mimetic mutant (T485E) was detected
at higher levels (232.1% ± 20.5%) relative to WT UBE3A (Figures
4A and 4B). Furthermore, inhibiting protein synthesis with cyclo-
heximide showed that the phospho-mimetic T485E mutant had
a longerproteinhalf-lifewhencompared to theT485Amutant (Fig-
ures S3A and S3B). Collectively, these data suggest that phos-
phorylation at T485 inhibits self-ubiquitination of UBE3A, thereby
increasing UBE3A levels, while dephosphorylation of T485 in-
creases UBE3A activity and self-degradation. Indeed, ubiquitin-
conjugated formsofUBE3Awereobservedwith theT485Amutant
but were not observed with the T485E mutant (Figure 4C). And,
levels of T485Awere elevatedwhen the proteasomewas inhibited
withMG-132 (FiguresS3CandS3D).Similar resultswereobtained
in cortical neurons—the T485Amutation reducedUBE3A levels in
neurons ascompared toWTUBE3A,whereas theT485Emutation
stabilized UBE3A levels (Figures 4D–4F).
Our mass-spectrometry analyses indicated that serine 489
(S489) was also phosphorylated (Figure S2D). And, the neigh-
boring serine 480 (S480) residue is located within a conserved
consensus site for Akt phosphorylation (Figure S3E). We
mutated each potential phosphorylation site in this region
(S489, S480, and Y488) to residues that cannot be phosphory-
lated (Ala or Phe) and then measured UBE3A levels by western
blotting. Unlike the T485A mutation, none of these additional
phosphorylation site mutations altered UBE3A levels (Figures
S3F and S3G), suggesting that T485 is the principal site for post-
translational regulation in this region.
Next, we examined the extent to which the T485A and T485E
mutants targeted substrates for ubiquitination. In vitro ubiquiti-
nation reactions were performed with S5a, a non-specific model
substrate that has been used to assess the activities of various
ubiquitin ligases (Jacobson et al., 2014). We performed our reac-
tions with WT or UBE3A mutants expressed and purified from
HEK293T cells. We found that the T485A mutant accelerated
the formation of S5a ubiquitin conjugates as compared to WTUBE3A, whereas the UBE3A T485E mutant behaved like the
ligase-dead UBE3A mutant (Figure 4G). We next monitored
ubiquitination in cells using HHR23A. Consistent with our
in vitro assays, the T485A mutant was hyperactive, generating
more HHR23A-ubiquitin conjugates relative to WT UBE3A,
whereasUBE3A-T485E did not ubiquitinate HHR23A (Figure 4H).
Moreover, HHR23A levels were directly correlated with UBE3A
levels in cells (Figure 4I and 4J). Taken together, these data sug-
gest that phosphorylation at T485 inhibits the ubiquitin ligase ac-
tivity of UBE3A toward itself and its substrates.
De Novo UBE3A T485A Mutation in an Autism Proband
As part of a recent whole-exome sequencing study, Iossifov and
colleagues identified one autism proband, out of thousands of
probands sequenced, with a de novo missense mutation in
UBE3A (Iossifov et al., 2014). Thisoneprobandwascharacterized
with autistic features, was near normal IQ, and possessed an A:G
substitution at chromosome 15:25,615,808, generating the same
T485A missense mutation that, as we found above, disrupts the
PKAphosphorylation site.We obtained immortalized lymphocyte
cell lines fromtheaffectedchild and theparents (Family ID: 13873)
and sequenced PCR-amplified fragments of genomic DNA en-
compassing T485. This analysis confirmed that the T485A muta-
tion was present only in the child with autism (Figure 5A).
Next, we assessed the relative abundance of endogenous
substrates (UBE3A, S5a, and HHR23A) in lymphocyte-derived
cell lines from the affected child and unaffected parents.
Remarkably, all three substrates were significantly reduced in
cells from the proband relative to the parents (Figures 5B–5E).
Collectively, our experiments indicate that T485A disables phos-
phorylation control over UBE3A ubiquitin ligase activity, leading
to hyperactivation of UBE3A and enhanced targeting of itself and
other substrates for degradation.
PKA Is an Upstream Regulator of UBE3A
Since T485 is located within a canonical PKA consensus motif,
we next evaluated the extent to which alterations in PKA activity
influence UBE3A protein levels. We first performed co-immuno-
precipitation experiments from cortical neuron lysates derived
from postnatal day 1 (P1), a time when UBE3A phosphorylation
peaks in the cortex (Figures S4A and S4B). We found that
UBE3A can exist in a complex with the catalytic subunit of PKA
(Figure 6A). Next, we tested whether UBE3A is a substrate of
PKAby performing an in vitro kinase assaywith recombinant pro-
teins andmonitoringUBE3Aphosphorylation usingour phospho-
specific antibody. We found that PKA phosphorylates UBE3A at
T485 in a time-dependent manner, demonstrating that UBE3A is
a direct substrate of PKA (Figures 6B and 6C). We next assessed
the functional significance of PKA phosphorylation on UBE3A
ubiquitin ligase activity. We subjected phosphorylated UBE3A
from our in vitro PKA reaction to an in vitro ubiquitination reaction
and found that phosphorylation profoundly inhibited UBE3A
ubiquitin ligase activity (Figure 6D). This effect was specific to
phosphorylation at T485, as PKA was incapable of inhibiting the
ubiquitin ligase activity of the T485Amutant (Figure 6D). Likewise,
co-expression of WT UBE3A with increasing amounts of
constitutively active PKA (PKA-CA) led to increased levels of
HHR23A, while HHR23A levels remained low in cells expressingCell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc. 799
Figure 4. Phosphorylation at T485 Inhibits UBE3A Ubiquitin Ligase Activity
(A and B) Representative western blot and quantification of HEK293T cells transfected with the indicated constructs. Values are shown as the percent of WT
UBE3A levels ± SE. n = 4, *p < 0.05, **p < 0.005, ***p < 0.0005.
(C) HEK293T cells transfected with the indicated Myc-UBE3A and FLAG-ubiquitin constructs were treated with the proteasome inhibitor MG-132 (30 mM, 4 hr).
UBE3A was immunoprecipitated using an anti-Myc antibody and was western blot probed with an anti-FLAG antibody to detect ubiquitinated UBE3A.
(D–F) Immunofluorescence staining and quantification of WT UBE3A and T485 mutants in DIV 10 mouse cortical neurons. Scale bar, 15 mm. Raw intensity values
for Myc immunofluorescence (E) or Myc immunofluorescence normalized to GFP (F) are shown as the mean intensity ± SE. T485A, n = 14; T485E, n = 16,
*p < 0.05, ***p < 0.0005.
(G) In vitro ubiquitination assay was performed using S5a as the substrate and UBE3A mutants expressed and purified from HEK293T cells. Reactions were
stopped after 4 hr, and the formation of high molecular weight polyubiquitinated S5a was monitored by western blot using an S5a antibody.
(H) HEK293T cells were transfected with the indicated Myc-UBE3A, FLAG-ubiquitin, and V5-HHR23A constructs and were treated with MG-132. HHR23A was
immunoprecipitated and western blot probed with an anti-FLAG antibody.
(I and J) Western blot and quantification of protein lysates from HEK293T cells transfected with the indicated constructs. Values are expressed as the mean
percent ± SE of protein levels in WT UBE3A-expressing cells. n = 4, ***p < 0.0005.
800 Cell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc.
Figure 5. A De Novo A>G (T485A) Missense Mutation in an Autism Proband Enhances UBE3A Substrate Turnover
(A) A genomic region of UBE3A from the father, the mother, and the autism proband was amplified and sequenced from immortalized lymphocyte cell lines (the
Simon’s Simplex Collection; Family ID: 13873).
(B–E) Endogenous protein levels of (C) UBE3A, (D) HHR23A, and (E) S5a in lymphocyte cell lines were quantified by western blot analysis. Protein levels were
normalized to actin and were shown as mean intensity ± SE. n = 3, *p < 0.05. A.U., arbitrary units.UBE3A-T485A and PKA-CA (Figures S4C and S4D). These data
suggest that PKA phosphorylation at T485 inhibits UBE3A ubiq-
uitin ligase activity in cells.
In neurons, overexpression of a dominant-negative PKA
mutant (PKA-DN) or expression of GFP fused to the PKA-spe-
cific inhibitory peptide PKI resulted in markedly reduced basal
phospho-UBE3A levels (Figures 6E and 6F). UBE3A phosphory-
lation at T485 was also reduced by KCl-induced depolarization
(Figures S4E and S4F), suggesting strong activation of an up-
stream UBE3A phosphatase by neuronal activity. In contrast,
phosphorylation was induced acutely with pharmacological
activators of PKA, including agents that stimulate cyclic-AMP
(cAMP) production, prevent cAMP breakdown, and activate
Gas signaling (Figures 6G and 6H). The PKA inhibitor KT5720
(5 mM) blocked all of these effects (Figures 6G and 6H). More-
over, we found that WT UBE3A levels increased when co-trans-
fected with PKA-CA and decreased when co-transfected with
PKA-DN, while the protein levels of the T485A mutant remained
lower and the T485E mutant remained higher than WT UBE3A
(Figures 6I and 6J). Self-degradation of the hyperactive AS
disease-causing mutants (T106P and I130T) could likewise be
rescued by co-expressing PKA-CA or by introducing the phos-
pho-mimetic T485E mutation (Figures S4G and S4H).
Our findings also suggested that it should be possible to inhibit
self-targeted UBE3A degradation by chronically increasing PKA
activity. Indeed, long-term treatment (48 hr) of neuronal cultures
with forskolin or a phosphodieterase-4 inhibitor (rolipram) signif-
icantly increased UBE3A protein levels (Figures 6K and 6L). Alto-
gether, these genetic and pharmacological data provide directevidence that PKA is the predominant upstream protein kinase
that phosphorylates UBE3A at T485.
Our findings raise the question of precisely how phosphoryla-
tion controls UBE3A ubiquitin ligase activity. Previous mapping
experiments identified a roughly 500 amino acid domain
(residues280–768) in UBE3A that is required for intermolecular
self-ubiquitination and interaction with E6-dependent substrates
(Huibregtse et al., 1993; Nuber et al., 1998). T485 is located cen-
trally within this domain; thus, we tested whether modifications
at T485 affect substrate binding. Indeed, the phospho-mutant
(T485A) showed strong interaction with itself and with HHR23A
in pull-down experiments, while WT UBE3A and the phospho-
mimetic mutant (T485E) showed little to no interaction with
substrates (Figures S4I and S4J). These data suggest that phos-
phorylation prevents UBE3A from binding to its substrate, hence
preventing UBE3A from marking substrates for degradation.
Phosphorylation does not appear to affect other aspects of
UBE3A catalysis. For example, the T485E phospho-mimetic
mutant retained its ability to form a thioester bond with ubiquitin
(Figure S4K). This suggested that phosphorylation does not
inhibit the transfer of ubiquitin from the E2 enzyme and does
not inhibit the conjugation of ubiquitin to the catalytic cysteine
of UBE3A. Moreover, the active form of UBE3A has been pro-
posed to exist as a homo-trimeric complex (Ronchi et al.,
2014). However, we did not detect homomeric interaction with
WT or T485E UBE3A (Figure S4I), and the T485Amutant retained
activity (as evidence by lower protein levels relative to WT) when
harboring a mutation (F727D) that reportedly destabilizes
trimeric UBE3A (Figures S4L and S4M).Cell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc. 801
Figure 6. PKA Regulates UBE3A Activity
(A) Co-immunoprecipitation from P1 mouse cortical lysate. Lysate was incubated with an anti-PKA-Ca antibody, and the immunoprecipitates were analyzed by
western blot with an anti-UBE3A antibody or no primary antibody as control.
(B and C) In vitro kinase assay showing phosphorylation of UBE3A by PKA. The reaction was performed with recombinant human PKA (catalytic subunit) and
recombinant humanUBE3A. Phosphorylation wasmonitoredwith the pT485UBE3A antibody and quantified in (C). Values are shown as the ratio of UBE3A pT485
intensity to total UBE3A intensity ± SE. n = 3, *p < 0.05, ***p < 0.0005.
(D) An in vitro kinase reaction was performedwith or without PKA usingWTUBE3A andUBE3A T485A expressed and purified fromHEK293T cells, followed by an
in vitro ubiquitin ligase reaction with the substrate S5a. Ubiquitination was monitored at time 0 and 4 hr by western blot with an anti-S5a antibody.
(E and F) PKA inhibition reduces basal levels of phosphorylated UBE3A in neurons. DIV 11 mouse cortical neurons were transfected with GFP, PKA-DN, or GFP
fused to the peptide inhibitor PKI (GFP-PKI). After 48 hr, cells were fixed and immunostained with antibodies against GFP, UBE3A pT485, and total UBE3A.
Arrowheads indicate the transfected GFP-positive neuron, and arrows indicate nearby untransfected neurons. Scale bar, 25 mm. UBE3A pT485A immunore-
activity is shown as the mean intensity ± SE in (F). GFP: n = 12, PKA-DN: n = 16, GFP-PKI: n = 16, ***p < 0.0005.
(G and H) Phosphorylation of UBE3A T485 in dissociated DIV 11 mouse cortical neurons following stimulation with forskolin (15 mM, 1 hr), rolipram (75 mM, 1 hr),
isoproterenol (10 mM, 1 hr), and inhibition of PKA with KT5720 (5 mM). (H) Quantification. Values were normalized to total UBE3A levels and are the mean
(legend continued on next page)
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Disruption of UBE3A Phosphorylation Impairs Dendritic
Spine Development In Vivo
A previous study found that chronic pharmacological inhibition
of PKA led to increased dendritic spine densities along with su-
pernumerary synapses (Lu et al., 2011). To determine whether
this effect was mediated by UBE3A, we chronically treated
E15.5 neurons from WT and Ube3am–/p+ mice with the small-
molecule inhibitor KT5720 (on DIV 19) and then processed cells
for the excitatory postsynaptic marker PSD-95 and the excit-
atory presynaptic marker vGLUT1 (Figures 7A and 7B). Consis-
tent with Lu and colleagues, we also found that WT neurons
treated with KT5720 exhibited a significant increase in the den-
sities of spines positive for PSD-95 and vGLUT1when compared
to DMSO (Figures 7A and 7C; WT DMSO, 0.54 ± 0.05; WT
KT5720, 0.81 ± 0.05, spines/mm of dendrite). Notably, however,
this effect was absent in Ube3am–/p+ neurons (Figures 7B and
7D; Ube3am–/p+ DMSO 0.56 ± 0.04; Ube3am–/p+ KT5720,
0.53 ± 0.05, spines/mm of dendrite). For WT neurons, these
changes were accompanied by an increase in the number of
paired or unpaired vGLUT1 and PSD-95 puncta (Figures S5A
and S5B), but they were not accompanied by obvious morpho-
logical changes in spines (Figure S5B). Moreover, chronic
KT5720 treatment also reduced levels of phosphorylated
UBE3A in spines and dendrites (Figures S5C–S5E). Altogether,
these experiments suggest that UBE3A is a principal effector
of PKA-dependent dendritic spine development.
Lastly, we investigated whether phosphorylation at T485
affected spine formation in vivo by introducing GFP, WT
UBE3A, the T485A, or the T485E mutants through in utero elec-
troporation into the cerebral cortex of E15.5 animals. We then
analyzed spines on primary basal dendrites of layer 2/3 pyrami-
dal neurons in the somatosensory cortex of young adult (post-
natal day 30 [P30]) mice (Figure 7E). Animals overexpressing
WT UBE3A showed a modest increase in dendritic spine den-
sities relative to the GFP control, while spine density increased
by 58% in mice expressing the hyperactive T485A mutant
(Figures 7F and 7G; GFP, 1.16 ± 0.05; UBE3A WT, 1.45 ± 0.08;
UBE3A-T485A, 1.83 ± 0.08, spines/mm dendrite). In addition,
dendritic head widths for both WT UBE3A and the T485Amutant
were significantly decreased (Figures S5F and S5G), indicating
subtle alterations to spine morphologies in addition to changes
in density. In contrast, expression of the inactive phospho-
mimetic T485E mutant had no effect on spine density (1.06 ±
0.06 spines/mm dendrite) or morphology relative to GFP-only
controls (Figures 7F, 7G, S5F, and S5G). Thus, expression of
a constitutively active, phosphorylation-defective version of
UBE3A (T485A) promoted excessive spine formation that per-
sisted into adulthood, while expression of the inactive phos-
pho-mimetic mutant did not alter spine number relative to the
control. These data collectively suggest that PKA-dependentpercentage ± SE of basal UBE3A phosphorylation. n = 5, *p < 0.05, **p < 0.005. S
inhibitor conditions.
(I and J) UBE3A T485 mutants are resistant to changes in PKA activity. Western b
cells with DN or CA-PKA. Values are shown as the mean percent ± SE of WT UB
(K and L) Chronic PKA activation increases the UBE3A levels in neurons. DIV 11 ne
and UBE3A levels were analyzed by western blot and (L) quantified. UBE3A valu
*p < 0.05.phosphorylation of UBE3A controls proper spine formation
during brain development (Figure 7H).
DISCUSSION
Phosphorylation at T485 Inhibits UBE3A Ubiquitin
Ligase Activity
We noticed that numerous disease-linkedmissensemutations in
UBE3A were distant from the active site and clustered together.
At the epicenter of one of these mutational hot spots was a PKA
phosphorylation site (T485). We found that this site can be phos-
phorylated in vitro, in cells, in neurons, and in the brain, and that
phosphorylation of this site inhibits UBE3A ubiquitin ligase activ-
ity toward itself and its substrates. Our in vitro and in vivo exper-
iments, including experiments with lymphocytes from an autism
proband harboring a phospho-mutant T485A missense muta-
tion, show that T485 phosphorylation serves as a master switch,
disengaging UBE3A from substrates and hence blocking UBE3A
enzymatic activity. Our study shows that UBE3A is regulated by
phosphorylation and that an autism-linkedmutation disables this
phosphorylation control and impairs synapse formation in vivo.
Two additional de novo missense variants were identified
in the autism proband that we studied (Family ID: 13873). These
variants include a V49I substitution in histone H2B type 1-J
(HIST1H2BJ) and an E90K substitution in laminin a4 (LAMA4)
(Iossifov et al., 2014). Although both variants await experimental
characterization, existing data do not support a role for these
variants in autism pathology. V49I is a conservative substitution,
and neither HIST1H2BJ nor LAMA4 are expressed in the human
brain (Su et al., 2004).
Collectively, our findings suggest that abnormal elevation of
UBE3A activity, caused by the T485A missense mutation, con-
tributes to autism pathology in this individual. Identifying addi-
tional autism-linked mutations that disrupt UBE3A T485 phos-
phorylation will strengthen this assertion. Moreover, our work
provides further evidence that excess UBE3A activity in the brain
increases risk for autism. Future studies will be needed to assess
phenotypic similarities between this genetically precise T485A
point mutation that hyperactivates UBE3A, 15q11-13 duplication
that elevates UBE3A and other genes, and a recently identified
family with a 15q11.2 duplication that encompasses only
UBE3A and that segregates with autistic features, develop-
mental delay, depression, and schizophrenia (Noor et al., 2015).
AS-Linked Mutations Destabilize UBE3A via Distinct
Loss- and Gain-of-Function Mechanisms
We found that most AS-linked missense mutations destabilize
UBE3A independent of ubiquitin ligase activity, making them
classic loss-of-function mutations. Our work also identified a
cluster of mutations (R477P, M478I, R482P) that were distanttatistical comparisons were made between appropriate agonist and agonist +
lot and quantification of the indicated constructs co-transfected into HEK293T
E3A levels. n = 6, **p < 0.005, ***p < 0.0005.
urons were cultured for 48 hr in the presence of 1 mM forskolin or 5 mM rolipram,
es were normalized to Tuj1 and are shown as the mean intensity ± SE. n = 3,
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Figure 7. UBE3A T485A Phospho-Mutant Abnormally Increases Dendritic Spine Formation In Vivo
(A) Confocal projections showing synapse formation in WT neurons treated with vehicle (DMSO, left) or 1 mMKT5720 (right) for 48 hr (DIV 19–21). Scale bar, 4 mm.
(B) Confocal projections showing synapse formation in Ube3am–/p+ neurons treated with vehicle (DMSO, left) or 1 mM KT5720 (right) for 48 hr (DIV 19–21). Scale
bar, 4 mm. GFP is shown in green, PSD-95 immunofluorescence in red, and vGLUT1 immunofluorescence in blue.
(C and D) Quantification showing increased spine densities with KT5720 treatment in WT neurons (C), but not inUbe3a m–/p+ neurons (D). Values are shown as the
mean spine densities ± SE. n = 25–30 neurons/condition; ***p < 0.0005.
(E) Low-magnification confocal image showing transfected neurons (green) in the cortex of young adult (P30) animals after in utero electroporation (IUE) at E15.5.
Nuclear stain DAPI (blue). Scale bar, 200 mm.
(F and G) Representative images of dendrites showing spine densities in neurons expressing the indicated constructs and quantification (G). Scale bar, 2 mm.
Values are shown as mean spine densities ± SE. n = 20–25 neurons/condition, *p < 0.05, ***p < 0.0005.
(H) Model of PKA and UBE3A signaling in spine growth. Text size is proportional to enzyme activity level.from the active site that blocked UBE3A substrate targeting. The
R477P, M478I, and R482P mutations all reside near the T485
phosphorylation site, and these mutations inhibited UBE3A in a
manner analogous to phosphorylation at T485. Given the impor-804 Cell 162, 795–807, August 13, 2015 ª2015 Elsevier Inc.tance of this region for substrate and homomeric interactions
(Figures S4I and S4J), these mutations likely act independent
of UBE3A phosphorylation and disrupt the docking of substrates
to UBE3A, thereby causing a loss of function. In support of this
mechanism, we found that the R482P mutation dominantly in-
hibited the hyperactive T485A mutation (Figures S5H and S5I).
Our study also identified mutations that differentially affect
UBE3A targeting of itself and other substrates. One cluster of
mutations (T106P, T106K, I130T) enhanced self-targeting
without affecting the targeting of other substrates. The converse
was found with mutations that flank the a1 helical region (I329T,
E550L). These mutations blocked substrate targeting without
affecting self-targeting. Collectively, our study highlights how
a rigorous characterization of disease-linked missense muta-
tions can provide fundamental new insights into enzyme catal-
ysis and enzyme regulation under normal and pathological
conditions.
Hyperactive UBE3ADrives Abnormal Spine Formation in
the Brain
We found that phosphorylation of UBE3A peaks in the first week
of postnatal life in themouse cerebral cortex, which corresponds
to a developmental windowwhen synaptic plasticity is driven pri-
marily by PKA signaling (Lu et al., 2007; Yasuda et al., 2003). PKA
might thus regulate UBE3A activity within the first 7 days of life
to allow for the proper progression of synapse development. In
support of this idea, we found that chronic PKA inhibition failed
to increase dendritic spine density in Ube3a-deficient neurons,
and overexpression of UBE3A-T485A, a mutant that cannot be
phosphorylated, profoundly increased dendritic spine density
in vivo. This increase in spine density persisted into young
adulthood (P30), suggesting that the hyperactive UBE3A
T485A mutant promotes long-lasting structural changes in the
brain. The T485A mutation was identified in a child with autism,
a disorder associated with increased spine number (Hutsler
and Zhang, 2010; Piochon et al., 2014; Tang et al., 2014), further
suggesting that the hyperactive UBE3A mutant contributes to
autism pathology. In light of our findings, a reduction in PKA
activity, which reduces phosphorylation at T485 and elevates
UBE3A activity (Figure 7H), might contribute to autism in a larger
number of patients than presently recognized.
Lastly, our findings have therapeutic implications. We found
that chronic treatment of neurons with pharmacological agents
that stimulate PKA can turn down UBE3A activity (Figures 6K
and 6L). This suggests that it may be possible to reduce
UBE3A activity in individuals with 15q11-13 duplication/triplica-
tion forms of autism using such agents. Excessive UBE3A
activity is also associated with the vast majority of all cervical
cancers (Pisani et al., 1999; Walboomers et al., 1999). Our find-
ings thus raise the possibility that targeting upstream regulators
of UBE3A could provide a general strategy for treating neuro-




C57BL/6 WT and Ube3am–/p+ mouse lines and associated genotyping proce-
dures have been previously described (Huang et al., 2012; Yashiro et al., 2009).
All animal experiments were approved by the Institutional Animal Care andUse
Committee of the University of North Carolina at Chapel Hill and in accordance
with NIH guidelines. Embryonic day 0.5 (E0.5) was defined as noon following
initiation of timed mating.Molecular Biology
The nomenclature used in this study is based on the amino acid sequence of
human UBE3A isoform I (accession: NP_570853.1). Detailed methods can be
found in the Supplemental Information.
Primary Neuron Cultures
Neuronal cultures were prepared from E13.5–E15.5 C57BL/6 WT or
Ube3am–/p+ mice as previously described (Huang et al., 2012). Mouse cortices
were dissected and trypsinized at 37C for 10 min and were dissociated with
a fire-polished Pasteur pipette in plating medium (neurobasal medium with
5%fetal bovine serum,Glutamax,B27 [Life Technologies]), andAntibiotic-Anti-
mycotic. Dissociated neurons were seeded onto 12- or 24-well plates with or
without coverslips coated with poly-D-lysine (0.1 mg/ml) at a density of about
526 cells/mm2. Cultured neurons were maintained at 37C with 5% CO2 and
were supplemented with neurobasal medium containing 4.84 mg/ml uridine
50-triphosphate (Sigma), 2.46 mg/ml 5-fluoro 2-deoxyuridine (Sigma), gluta-
max, B27, and 13 antibiotic-antimycotic at days in vitro (DIV) 3 and 9.
In Utero Electroporation
Embryos (E15.5) from timed-pregnant CF-1 females were isolated and their
lateral ventricles injected with 1–2 mg of plasmid DNA. Five electrical pulses
were delivered at 30 V (50 ms duration) with a 950 ms interval using 5 mm
paddle electrodes. The embryos were then placed back into the female.
After birth, the neonates were transferred on postnatal day 1 (P1) to foster
mothers. At P30, mice were sacrificed and their brains processed for
analysis.
Statistical Analysis
Statistical analyses were performed using the GraphPad Prism software. Sta-
tistical treatments for each experiment can be found in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2015.06.045.
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